James George to Aged
This is a "connection" page, showing publications James George has written about Aged.
Connection Strength
1.488
-
Preventable deaths during initial episodes of acquired Thrombotic Thrombocytopenic Purpura: Past and future. Am J Hematol. 2019 09; 94(9):E242-E244.
Score: 0.083
-
Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. Am J Hematol. 2017 Nov; 92(11):E644-E646.
Score: 0.073
-
Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients. Am J Kidney Dis. 2017 Nov; 70(5):686-695.
Score: 0.073
-
Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion. 2017 10; 57(10):2532-2538.
Score: 0.072
-
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016 06 16; 127(24):3092-4.
Score: 0.066
-
Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol. 2015 Aug; 90(8):709-14.
Score: 0.062
-
Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011 to 2014. Transfusion. 2014 Dec; 54(12):3257-9.
Score: 0.060
-
Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency. Am J Kidney Dis. 2014 Aug; 64(2):317-8.
Score: 0.058
-
Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim. Eur J Haematol. 2013 Oct; 91(4):376-7.
Score: 0.055
-
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013 Sep 19; 122(12):2023-9; quiz 2142.
Score: 0.055
-
Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012 Sep; 87(9):848-52.
Score: 0.051
-
Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program. 2012; 2012:604-9.
Score: 0.049
-
Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011 Sep; 86(9):743-51.
Score: 0.048
-
The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010 Mar; 85(3):174-80.
Score: 0.043
-
Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients. Am J Hematol. 2009 Jul; 84(7):459-61.
Score: 0.041
-
Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion. 2009 Feb; 49(2):392-4.
Score: 0.040
-
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009 Feb; 144(3):409-15.
Score: 0.040
-
Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009 Jan; 49(1):118-24.
Score: 0.039
-
Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol. 2008 May; 141(5):696-707.
Score: 0.038
-
Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion. 2008 Feb; 48(2):349-57.
Score: 0.037
-
Endemic Esherichia coil O157:H7 infections and hemolytic-uremic syndrome in Oklahoma, 2002-2005. J Okla State Med Assoc. 2007 Nov; 100(11):429-33.
Score: 0.037
-
The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005 Jul; 3(7):1432-6.
Score: 0.031
-
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004 Jan; 41(1):60-7.
Score: 0.028
-
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003 Nov; 74(3):161-9.
Score: 0.028
-
Idiopathic thrombocytopenic purpura and myelodysplastic syndrome: distinct entities or overlapping syndromes? Leuk Res. 2002 Sep; 26(9):789-90.
Score: 0.026
-
Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001 Dec 18; 135(12):1047-51.
Score: 0.025
-
Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood. 2021 06 24; 137(25):3563-3575.
Score: 0.024
-
Occult quinine-induced thrombocytopenia. J Okla State Med Assoc. 2000 Nov; 93(11):519-21.
Score: 0.023
-
The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019 10; 104(10):2107-2115.
Score: 0.020
-
Clinical decisions in idiopathic thrombocytopenic purpura. Hosp Pract (1995). 1997 Sep 15; 32(9):159-60, 163-6, 169-70, passim.
Score: 0.018
-
Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol. 2014 Feb; 92(2):156-63.
Score: 0.014
-
Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev. 2013 Jul; 27(3):137-45.
Score: 0.014
-
A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia. Eur J Haematol. 2013 Feb; 90(2):121-6.
Score: 0.013
-
Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. Transfusion. 2012 Jul; 52(7 Pt 2):1614-21.
Score: 0.013
-
Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion. 2011 Oct; 51(10):2237-43.
Score: 0.012
-
Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2011 May; 86(5):420-9.
Score: 0.012
-
Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient perspectives. Eur J Haematol. 2009 Nov; 83(5):497-8.
Score: 0.010
-
Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009 Sep; 83(3):175-82.
Score: 0.010
-
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 02; 371(9610):395-403.
Score: 0.009
-
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008 Feb; 83(2):150-4.
Score: 0.009
-
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 Oct 19; 355(16):1672-81.
Score: 0.009
-
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8.
Score: 0.007
-
Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13.
Score: 0.005
-
The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
Score: 0.005